Azacitidine - Indications, Dosage, Side Effects and Precautions

USDailyMed:Azacitidine AU:X (High risk) L01BC07(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only 4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one 320-67-2Y 9444 6796 DB00928Y 9072Y M801H13NRU D03021Y CHEBI:2038Y ChEMBL1489Y DTXSID9020116 Interactive image O=C1/N=C(\N=C/N1[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO)N InChI=1S/C8H12N4O5/c9-7-10-2-‍‍‍‍‍‍​​​‍​​​​​​12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1YKey:NMUSYJAQQFHJEW-KVTDHHQDSA-NY Azacitidine, sold under the brand nameVidazaamong others, is amedicationused for the treatment ofmyelodysplastic syndrome,myeloid leukemia,andjuvenile myelomonocytic leukemia.It is a chemicalanalogofcytidine, anucleosideinDNAandRNA.[medical citation needed]Azacitidine and its deoxy derivative,decitabine(also known as 5-aza-2′-deoxycytidine) were first synthesized inCzechoslovakiaas potentialchemotherapeutic agentsfor cancer. The most common adverse reactions in children with juvenile myelomonocytic leukemia include pyrexia, rash, upper respiratory tract infection, and anemia.